PURPOSE: With the increasing number of elderly patients suffering from cancer, comorbidity and functional impairment become common problems in patients with cancer. Both comorbidity and functional impairment are associated with a shorter survival time in cancer patients, but their independent role has rarely been addressed before. METHODS: Within a prospective trial we recruited 427 cancer patients, irrespective of age and type of cancer, admitted as inpatients prior to the start of chemotherapy. Comorbidity was assessed with the cumulative illness rating scale (CIRS-G), functional impairment with WHO performance status (WHO-PS), basal (ADL) and instrumental (IADL) activities of daily living. RESULTS: Median follow-up was 34.2 months. A total, 61.4%. of patients died. Median survival time was 21.0 months. Age, kind of tumour (solid vs. haematological), treatment approach (non-curative vs. curative), WHO-PS (2-4 vs. 0-1), IADL (<8 vs. 8), and severe comorbidity (CIRS-level 3-4 vs. none) were significantly associated with shorter survival time in univariate analysis. In a multivariate Cox-regression-analysis, age (HR 1.019; 95%-CI 1.007-1.032; P=0.003), kind of tumour (HR 1.832; 95%-CI 1.314-2.554; P<0.001), WHO-PS (HR 1.455; 95%-CI 1.059-2.000; P=0.021), and comorbidity level 3-4 (HR 1.424; 95%-CI 1.012-2.003; P=0.043) maintained their significant association. CONCLUSIONS: Age, severe comorbidity, functional impairment, and kind of tumour are independently related to shorter survival time in cancer patients.
PURPOSE: With the increasing number of elderly patients suffering from cancer, comorbidity and functional impairment become common problems in patients with cancer. Both comorbidity and functional impairment are associated with a shorter survival time in cancerpatients, but their independent role has rarely been addressed before. METHODS: Within a prospective trial we recruited 427 cancerpatients, irrespective of age and type of cancer, admitted as inpatients prior to the start of chemotherapy. Comorbidity was assessed with the cumulative illness rating scale (CIRS-G), functional impairment with WHO performance status (WHO-PS), basal (ADL) and instrumental (IADL) activities of daily living. RESULTS: Median follow-up was 34.2 months. A total, 61.4%. of patients died. Median survival time was 21.0 months. Age, kind of tumour (solid vs. haematological), treatment approach (non-curative vs. curative), WHO-PS (2-4 vs. 0-1), IADL (<8 vs. 8), and severe comorbidity (CIRS-level 3-4 vs. none) were significantly associated with shorter survival time in univariate analysis. In a multivariate Cox-regression-analysis, age (HR 1.019; 95%-CI 1.007-1.032; P=0.003), kind of tumour (HR 1.832; 95%-CI 1.314-2.554; P<0.001), WHO-PS (HR 1.455; 95%-CI 1.059-2.000; P=0.021), and comorbidity level 3-4 (HR 1.424; 95%-CI 1.012-2.003; P=0.043) maintained their significant association. CONCLUSIONS: Age, severe comorbidity, functional impairment, and kind of tumour are independently related to shorter survival time in cancerpatients.
Authors: Paolo Maione; Francesco Perrone; Ciro Gallo; Luigi Manzione; FrancoVito Piantedosi; Santi Barbera; Silvio Cigolari; Francesco Rosetti; Elena Piazza; Sergio Federico Robbiati; Oscar Bertetto; Silvia Novello; Maria Rita Migliorino; Adolfo Favaretto; Mario Spatafora; Francesco Ferraù; Luciano Frontini; Alessandra Bearz; Lazzaro Repetto; Cesare Gridelli; Emiddio Barletta; Maria Luisa Barzelloni; Rosario Vincenzo Iaffaioli; Ermelinda De Maio; Massimo Di Maio; Gianfranco De Feo; Giuseppe Sigoriello; Paolo Chiodini; Angela Cioffi; Vincenzo Guardasole; Valentina Angelini; Antonio Rossi; Domenico Bilancia; Domenico Germano; Alfredo Lamberti; Vittorio Pontillo; Luigi Brancaccio; Francesco Renda; Francesco Romano; Gabriella Esani; Anna Gambaro; Orazio Vinante; Giuseppe Azzarello; Maurizia Clerici; Roberto Bollina; Paolo Belloni; Mirella Sannicolò; Libero Ciuffreda; Giuseppe Parello; Mary Cabiddu; Cosimo Sacco; Angela Sibau; Gianfranco Porcile; Federico Castiglione; Oliviero Ostellino; Silvio Monfardini; Micaela Stefani; Giorgio Scagliotti; Giovanni Selvaggi; Filippo De Marinis; Olga Martelli; Giampietro Gasparini; Alessandro Morabito; Domenico Gattuso; Giuseppe Colucci; Domenico Galetta; Francesco Giotta; Vittorio Gebbia; Nicola Borsellino; Antonio Testa; Emilia Malaponte; Matteo A Capuano; Michele Angiolillo; Francesco Sollitto; Umberto Tirelli; Simona Spazzapan; Vincenzo Adamo; Giuseppe Altavilla; Antonio Scimone; Maria Raffaella Hopps; Francesco Tartamella; Giovanni Pietro Ianniello; Vincenza Tinessa; Giuseppe Failla; Roberto Bordonaro; Nicola Gebbia; Maria Rosaria Valerio; Modesto D'Aprile; Enzo Veltri; Maurizio Tonato; Samir Darwish; Sante Romito; Francesco Carrozza; Sandro Barni; Antonio Ardizzoia; Giuliana Mara Corradini; Gianfranco Pavia; Mario Belli; Giuseppe Colantuoni; Enzo Galligioni; Orazio Caffo; Roberto Labianca; Antonello Quadri; Enrico Cortesi; Giuliana D'Auria; Sergio Fava; Anna Calcagno; Gino Luporini; M Cristina Locatelli; Francesco Di Costanzo; Silvia Gasperoni; Luciano Isa; Paola Candido; Fernando Gaion; Giovanni Palazzolo; Giuseppe Nettis; Anselmo Annamaria; Massimo Rinaldi; Massimo Lopez; Raffaella Felletti; Giorgio Bernabò Di Negro; Nestore Rossi; Antonio Calandriello; Luigi Maiorino; Rodolfo Mattioli; Alfredo Celano; Stefania Schiavon; Alfonso Illiano; Carlo Alberto Raucci; Michele Caruso; Paolo Foa; Giuseppe Tonini; Carlo Curcio; Marina Cazzaniga Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: David L Boulos; Patti A Groome; Michael D Brundage; D Robert Siemens; William J Mackillop; Jeremy P W Heaton; Karleen M Schulze; Susan L Rohland Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: William L Read; Ryan M Tierney; Nathan C Page; Irene Costas; Ramaswamy Govindan; Edward L J Spitznagel; Jay F Piccirillo Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: C Barrett Bowling; Gregg C Fonarow; Kanan Patel; Yan Zhang; Margaret A Feller; Xuemei Sui; Steven N Blair; Kannayiram Alagiakrishnan; Inmaculada B Aban; Thomas E Love; Richard M Allman; Ali Ahmed Journal: Eur J Heart Fail Date: 2012-04-04 Impact factor: 15.534
Authors: Sushma Jonna; Leslie Chiang; Jingxia Liu; Maria B Carroll; Kellie Flood; Tanya M Wildes Journal: Support Care Cancer Date: 2016-07-27 Impact factor: 3.603